Physician profile
Gregory Langas
NPI 1235209644
$876.04
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.24 · 2020: $144 · 2021: $208 · 2022: $171 · 2023: $189 · 2024: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $216.33 | 2020-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbvie INC. | $127.14 | 2020-2021 | |
| Cumberland Pharmaceuticals, INC. | $82.87 | 2020-2024 | Kristalose |
| Sanofi Pasteur INC. | $82.17 | 2020-2023 | |
| Cranial Technologies, INC | $76.99 | 2021-2024 | Doc Band |
| Alk-Abello, INC | $43.21 | 2023 | Grastek, Ragwitek, Odactra |
| Therapeuticsmd, INC. | $40.31 | 2020-2022 | |
| Organon LLC | $34.73 | 2023-2024 | Nexplanon |
| Pfizer INC. | $34.39 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $31.23 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.23 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $19.22 | 2024 | Relexxii |
| Roche Diagnostics Corporation | $17.16 | 2019 | |
| Glaxosmithkline, LLC. | $14.97 | 2023 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $13.19 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $12.90 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Langas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.